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Abstract
Background: The treatment of Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)
patients who harbor the T315I BCR-ABL1 mutation or who have two or more mutations in the same BCR-ABL1
molecule is particularly challenging since first and second-generation Tyrosine Kinase Inhibitors (TKIs) are ineffective.
Ponatinib, blinatumomab, chemotherapy and transplant are the currently available options in these cases.
Case presentation: We here report the case of a young Ph+ ALL patient who relapsed on front-line dasatinib
therapy because of two independent T315I-positive subclones, resulting from different nucleotide substitutions
-one of whom never reported previously- and where additional mutant clones outgrew and persisted despite
ponatinib, transplant, blinatumomab and conventional chemotherapy. Deep Sequencing (DS) was used to dissect
the complexity of BCR-ABL1 kinase domain (KD) mutation status and follow the kinetics of different mutant clones
across the sequential therapeutic approaches.
Conclusions: This case presents several peculiar and remarkable aspects: i) distinct clones may acquire the same
amino acid substitution via different nucleotide changes; ii) the T315I mutation may arise also from an ‘act’ to ‘atc’
codon change; iii) the strategy of temporarily replacing TKI therapy with chemo or immunotherapy, in order to
remove the selective pressure and deselect aggressive mutant clones, cannot always be expected to be effective;
iv) BCR-ABL1-mutated sub-clones may persist at very low levels (undetectable even by Deep Sequencing) for long
time and then outcompete BCR-ABL1-unmutated ones becoming dominant even in the absence of any TKI
selective pressure.
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Background
First and second-generation Tyrosine Kinase Inhibitors
approved for the treatment of Philadelphia-chromosome
positive Acute Lymphoblastic Leukemia have Achilles
heels that the BCR-ABL1 target oncoprotein may exploit
to escape from inhibition: point mutations in the kinase
domain may be selected that impair TKI binding [1–4].
Particularly challenging is the treatment of patients with
the T315I mutation and of patients with multi-TKI re-
sistant disease who harbor two or more mutations in the
same BCR-ABL1 molecule (compound mutants), where
first and second-generation TKIs are ineffective [5, 6].
Patients positive for the T315I mutation may now bene-
fit from the third-generation TKI ponatinib, that has the
ability to bind and inhibit every single kinase domain
mutant [7]. It remains unclear whether ponatinib effi-
cacy may be reduced by some compound mutants in-
cluding the T315I plus another dasatinib or nilotinib-
resistant mutation, since contrasting in vitro and in vivo
data have been reported [8]. An alternative rescue strat-
egy may be to ease the TKI selective pressure by
switching to chemotherapy or immunotherapy whose ef-
ficacy should not be influenced by patient mutation sta-
tus [9, 10]. We here report the case of a young patient
who relapsed on front-line dasatinib therapy because of
two independent T315I-positive subclones, resulting
from different nucleotide substitutions never reported
previously and where additional mutant clones outgrew
and persisted despite ponatinib, transplant, blinatumo-
mab and conventional chemotherapy. Deep Sequencing
was used to dissect the complexity of BCR-ABL1 KD
mutation status and follow the kinetics of different mu-
tant clones across the sequential therapeutic approaches.
Case presentation
The patient was a 19-years-old man who, despite very good
clinical conditions, presented with abnormal peripheral
blood counts before receiving a scheduled surgical proced-
ure. Physical examination revealed only a moderate spleno-
megaly. He was hyperleucocytotic, with a peripheral WBC
count of 40.7×109/L, a normal hemoglobin value and a
moderate thrombocytopenia. A bone marrow aspirate
showed 88% lymphoblasts, expressing the CD19, CD10,
CD22, CD34, CD58, and CD45 antigens. Chromosome
banding analysis of bone marrow revealed a normal karyo-
type; however, polymerase chain reaction revealed the
BCR-ABL1 e1a2 fusion transcript. BCR-ABL1 transcript
level assessed by real-time quantitative RT-PCR (RQ-PCR)
was 111.09%. No involvement of central nervous system
was detected, since all lumbar punctures performed
showed the absence of leukemic cells in cerebrospinal fluid.
Thus, a diagnosis of BCR-ABL1 (p190)-positive B-ALL was
made. After informed consent was obtained, treatment was
initiated according to the GIMEMA LAL1509 clinical trial
that included a steroid-based pre-phase, followed by dasati-
nib induction therapy at 140 mg/daily for 84 days. After
52 days of dasatinib therapy, the patient obtained a
complete hematological response with a mild decrease of
the BCR-ABL1 transcript levels (1.22%). At day 85 the pa-
tient unfortunately progressed. Conventional Sanger Se-
quencing analysis showed evidence of a C to T nucleotide
substitution at position 1091 of the ABL1 sequence in a
proportion of BCR-ABL1 transcripts, resulting in the
dasatinib-resistant T315I mutation. According to protocol
schedule, the patient was treated with one course of stand-
ard chemotherapy, consisting of clofarabine 80 mg/daily,
for 5 days and cyclophosphamide 800 mg/daily, for 5 days.
The patient achieved complete hematological remission,
but persistence of the BCR-ABL1 fusion transcript at the
molecular level was observed (1.69%). A severe cardiac
toxicity contraindicated the administration of an additional
course of consolidation chemotherapy. Therefore, because
of the minimal residual disease persistence, the patient was
enrolled in the MT103–203 clinical study of blinatumo-
mab, an anti-CD19 T cell engager antibody, as continuous
intravenous infusion for 28-days cycles. After one course
of treatment with 15 mcg/sqm/daily, which was well toler-
ated, a brilliant response was observed: the BCR-ABL1
transcript level significantly decreased down to 0.008% and
the T315I mutation disappeared at conventional sequen-
cing analysis. In consideration of the persistently subopti-
mal heart function, which would have seriously
compromised the outcome of a transplantation procedure,
a second course of therapy with blinatumomab was then
started two weeks after the end of the first one, as required
by protocol schedule. Unfortunately, the patient suddenly
and unexpectedly relapsed after 10 days, with a remarkable
hyperleucocytosis and a high percentage of lymphoblasts,
with the same immunophenotypic signature detected at
diagnosis. Conventional Sanger Sequencing showed that
the T315I mutation had reappeared in a proportion of
BCR-ABL1 transcripts. Salvage therapy with ponatinib at
the dosage of 45 mg/daily was immediately started, but
despite a very good tolerance to the compound, only a
hematological improvement was observed, without signifi-
cant changes in BCR-ABL1 transcript levels. At this time-
point, conventional Sanger Sequencing analysis displayed
an unusual pattern of nucleotide substitutions: a C to T
substitution at position 1091 and a T to C substitution at
the adjacent 1092 position, suggesting the presence of two
clones that could not be further characterized. Deep Se-
quencing was then performed as detailed in Soverini et al.
[11]; a median of 4166 (range, 2519–10,297) high quality
reads were obtained across the different runs. The analysis
demonstrated that two distinct T315I-positive subclones
were coexisisting: one subclone, with a relative abundance
of 58%, had the usual ‘act’ to ‘att’ codon shift resulting from
the c.1091c>t nucleotide change, whereas the other one,
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with a relative abundance of 47.14%, had both a c.1091c>t
and a c.1092 t>c nucleotide change, thus leading to an ‘act’
to ‘atc’ codon shift still translating into a threonine to iso-
leucine amino acid change at position 315 (Fig. 1). Since
TKI resistant BCR-ABL1 mutations existing prior to ex-
posure may exist, we looked for the T315I mutation at
diagnosis prior to dasatinib start, but Deep Sequencing
didn’t find evidence. Deep Sequencing was then used to
retrospectively investigate all the previous samples and re-
vealed that the two distinct T315I-positive subclones were
detectable since day 52 of dasatinib therapy, where both
were identified at very low level: T315I act>att 0.56% and
T315I act>atc 1.44%. At day 85, when the patient had re-
lapsed on dasatinib, the proportions of the two clones had
increased to 82,17% and 15.49% respectively. After chemo-
therapy, the T315I act>att subclone accounted for 100% of
BCR-ABL1 transcripts, and then became undetectable, too,
after the first course of blinatumomab. However, both sub-
clones had quickly become detectable again by Deep Se-
quencing (act>att 79.91%; act>atc 7.06%) when the patient
had relapsed during the second cycle. In the presence of a
matched-related stem cell donor, and in the absence of fur-
ther available therapeutic tools, the patient underwent allo-
geneic transplantation, with a conditioning regimen
consisting of fludarabine, busulfan and thiotepa, in addition
to ATG as graft-versus-host disease prophylaxis. A total of
16.12×108/kg nucleated cells were infused, including
7.4×106/kg CD34+ cells. No signs or symptoms of graft-
versus-host disease occurred, and a full recovery on per-
ipheral blood was observed after 16 days from transplant-
ation. After one month from this procedure, the bone
marrow evaluation showed a complete morphological re-
mission. FISH analysis revealed an almost complete full
donor chimerism; BCR-ABL1 transcript level was 0.48%.
Although the mutation analysis performed by conventional
sequencing did not show evidence of mutations, the
greater sensitivity of Deep Sequencing allowed to identify,
again, both the T315I-positive subclones at very low levels
(act>att 1.27%; act>atc 0.77%). After 3 months from allo-
geneic stem cell transplantation, despite good clinical con-
ditions and in the absence of symptoms of leukemia
progression, the patient developed hyperleukocytosis, with
mild anemia and thrombocytopenia. Bone marrow analysis
showed a full hematological relapse, confirmed by a
marked increase in BCR-ABL1 fusion transcripts (65.3%).
The Deep Sequencing analysis performed at this time point
showed the quick regrowth of both T315I-mutated sub-
clones (act>att 44%; act>atc 9.16%). Unexpectedly, the first
clone was found to harbor additional point mutations: the
F359V (16.34%) and H396R (9.47%). The rapid worsening
of peripheral hematological values required an immediate
therapeutic intervention. Therefore, after a brief and inef-
fective course of steroids and 6-mercaptopurine and hy-
droxyurea as cytoreductive agents, the patient received
salvage chemotherapy according to HAM schedule with
high dose of cytarabine and mitoxantrone. Treatment was
well tolerated, but subsequent iatrogenic bone marrow
aplasia was complicated by a severe pulmonary infection,
with microbiological and radiological images diagnostic for
an invasive fungal infection. Therefore, the patient received
dual antimycotic therapy with voriconazole and liposomal
amphotericin b, achieving a significant improvement of im-
aging reports after 3 weeks of treatment. Bone marrow
examination, which was performed one month after the
end of chemotherapy, showed the persistence of a relevant
amount of CD19+ lymphoid blast cells and BCR-ABL1
transcript level had further increased (87.8%). Deep Se-
quencing analysis showed again all the sub-clones pre-
viously identified T315I act>att (17.93%), T315I act>atc
(67%), F359V (3.17%), H396R (0.73%). At this time
point we observed the emergence of the Y253H point
mutation, with an abundance of 5.05%. Two T315I-
Fig. 1 Example of clonal analysis for sample ALL-8. a) Conventional Sanger Sequencing results showing the double nucleotide substitution at codon
315; b) screenshot showing a portion of the global alignment of sequence reads obtained with AVA software, where codon 315 maps. Deep Sequencing
allowed to resolve two distinct populations of mutants at this codon, one harboring the T315I (att) and one harboring the T315I (atc). Sequence were
compared to the wild-type sequence (green at the top) using BLAST, GenBank Accession Number X16416
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inclusive compound mutations were observed: T315I
act>att + F359V (0.67%) and the T315I act>atc + Y253H
(3.98%) (Fig. 2). In the following days, due to the onset
of specific symptoms, related with leukemic progres-
sion, mainly represented by fever and lumbar pain, the
patient received further cytoreductive chemotherapy,
obtaining a partial response. Unfortunately, the patient
developed a severe fungal pulmonary infection, and he
died two months after, in progression disease. An over-
view of the BCR-ABL1 transcript levels, for each time
point, assessed by real-time quantitative RT-PCR is re-
ported in Fig. 3. Results of BCR-ABL1 KD mutation
analysis performed by conventional Sanger sequencing
and Deep Sequencing are reported in Additional file 1
Table S1.
Discussion and conclusions
The case herein reported presents several peculiar and re-
markable aspects. First of all, this patient developed two
distinct dasatinib-resistant subclones, where the same
T315I amino acid substitution was acquired via different
nucleotide changes – a phenomenon of ‘convergent evolu-
tion’ that once again underlines how Darwinian theories
well apply to cancer [12]. Notably, in one of the two sub-
clones the T315I resulted from a previously unreported ‘act’
to ‘atc’ codon change, which requires two nucleotide substi-
tutions. Whether the ‘atc’ subclone arose from a ‘ct’ to ‘tc’
dinucleotide change, or rather derived from the ‘T315I
canonical’ ‘att’ mutant clone after a ‘t’ to ‘c’ mutation at the
third codon position, is impossible to tell. However, the fact
that the subclones were first detected by Deep Sequencing
after only 52 days of dasatinib treatment and, at that
time, they had identical abundance, would suggest a
simultaneous independent origin. Both the T315I-positive
subclones quickly became undetectable, even by Deep Se-
quencing, after only one course of blinatumomab but they
even more quickly re-emerged during the second course –
although blinatumomab is likely to be equally active against
B-cells harboring mutated or unmutated BCR-ABL1. Inter-
estingly, the T315I-positive clones persisted during ponati-
nib therapy, which was ineffective. Most likely, these two
clones happened to carry some cellular or molecular mech-
anism of resistance to ponatinib, which became the real
driver. Allogeneic hematopoietic stem cell transplantation
failed to deplete the BCR-ABL1 mutated clones. After
transplantation, in the absence of any kind of therapy, the
patient quickly relapsed with the re-emergence of the two
T315I-positive subclones. Even more inexplicably, add-
itional BCR-ABL1 kinase domain mutations became detect-
able in the same or different subclones during subsequent
salvage chemotherapy. The emergence of several T315I-
inclusive compound mutations was observed after 3 months
from allogeneic transplantation. When did they arise? Re-
cent in vitro studies have shown that accumulation of more
than one mutation within the same allele may be associated
with increased oncogenic potential. They have also sug-
gested that some T315I-inclusive compound mutants are
highly resistant to all second-generation TKIs and not al-
ways fully sensitive to ponatinib [8]. It can be hypothesized
that the mutants newly detected after transplant and after
subsequent salvage chemotherapy indeed originated in very
few Ph+ cells during ponatinib therapy, though they did
not have the time to outgrow and become detectable by
Deep Sequencing. It may even be hypothesized that they
originated earlier, during dasatinib therapy, or present since
diagnosis in very few Ph+ cells. In conclusion, we observed
Fig. 2 Overview of BCR-ABL1 KD mutations dynamics and their relative frequency at different time-points during treatment. Graphical illustration
of the kinetics of mutated population abundances for each time points in relation to therapeutic intervention
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that the T315I mutation may be acquired via different nu-
cleotide changes - also from an’ act’ to ‘atc’ codon change-
and may persist despite ponatinib or transplant. In addition
the strategy of temporarily replacing TKI therapy with
chemo or immunotherapy, in order to remove the selective
pressure and deselect aggressive mutant clones, cannot al-
ways be expected to be effective. The BCR-ABL1-mutated
sub-clones may persist at very low levels for long time and
then outcompete BCR-ABL1-unmutated ones becoming
dominant even in the absence of any TKI selective
pressure.
Additional files
Additional file 1: Comparison between mutations detected by conventional
Sanger sequencing and Deep sequencing and estimated clonal composition of
the samples. Mutation-relative abundance of conventional Sanger Sequencing
results was assessed on the basis of variant peak height. In the TKI/treatment
column, the TKI or the treatment being administered at the time of analysis is
indicated. In sample ALL-8 and 11, “T315?” denotes that 2 overlapping peaks at
adjacent positions (c/t at 1091 and t/c at 1092) of codon 315 were identified in
the Sanger Sequencing chromatogram and the resulting amino acid
substitution(s) could not be resolved. (PDF 209 kb)
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